세계의 집단검진 시장 보고서(2025년)
Population Screening Global Market Report 2025
상품코드 : 1824443
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,469,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,350,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,232,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

집단검진 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.2%로 414억 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 개인화된 의료로의 이동, 노화와 만성 질환, AI와 데이터 분석의 통합, 스크리닝에 대한 접근 확대 등에 기인할 수 있습니다. 예측 기간의 주요 동향에는 의료 기술의 진보, 유전체학 및 정밀 스크리닝, 원격 의료 및 원격 스크리닝, 다중 질환 스크리닝 패널, 건강의 공정성과 접근성이 포함됩니다.

향후 5년간의 성장률 7.2%라고 하는 예측은 전회의 예측으로부터 0.2%의 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세 영향 때문입니다. 관세장벽은 영국과 스웨덴에서 공급되는 인공지능을 탑재한 스크리닝 소프트웨어나 리퀴드 액체 생검 도구의 비용을 증가시켜 미국을 저해하고, 조기 발견률을 저하시키고, 공중위생 프로그램의 비용을 상승시킬 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

암의 유병률 증가는 향후 집단검진 시장의 성장을 견인할 것으로 예측됩니다. 암은 인체의 특정 세포가 비정상적으로 증식하고 신체의 다른 부위로 전이함으로써 발생합니다. 집단검진은 암의 조기 발견을 촉진하고, 치료 가능성을 높이고, 예후를 개선할 수 있습니다. 예를 들어, 2023년 1월 미국의 임의단체인 미국암협회(American Cancer Society Inc.)의 보고에 따르면 2022년 암 사망자 수는 60만 8,570명이며, 2021년 암 사망자 수 60만 6,520명과 비교하여 약 190만 건의 신규 암 사례가 발생한 것으로 추정됩니다. 따라서 암의 유병률 상승이 집단검진 시장의 성장을 가속하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Population screening is a systematic process aimed at evaluating the prevalence of a specific trait or disease within an entire population or a subgroup. The objective is to effectively identify individuals or groups at risk of developing a particular condition, distinguishing it from diagnostic testing.

The primary products associated with population screening include hardware equipment, testing or laboratory services, and analytics or interpretation tools. Hardware assumes a pivotal role in population screening by providing essential tools and equipment necessary for conducting screening tests, collecting data, and delivering healthcare services. Businesses engaged in population screening cater to various age groups, including males and females under 15, those between 15 and 65, and individuals aged 65 and above. These screening services are typically offered by a range of entities, including hospitals, research institutes, and diagnostic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The population screening research report is one of a series of new reports from The Business Research Company that provides population screening market statistics, including the population screening industry's global market size, regional shares, competitors with population screening market share, detailed population screening market segments, market trends and opportunities, and any further data you may need to thrive in the population screening industry. This population screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The population screening market size has grown strongly in recent years. It will grow from $29.31 billion in 2024 to $31.39 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to disease prevention initiative, government health policies, rising healthcare costs, increased disease awareness.

The population screening market size is expected to see strong growth in the next few years. It will grow to $41.4 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to shift towards personalized medicine, aging population and chronic diseases, integration of ai and data analytics, expansion of screening access. Major trends in the forecast period include advancements in medical technology, genomics and precision screening, telehealth and remote screening, multi-disease screening panels, health equity and accessibility.

The forecast of 7.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of Artificial intelligence-powered screening software and liquid biopsy tools sourced from the UK and Sweden, thereby reducing early detection rates and elevating public health program costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of cancer is projected to drive the growth of the population screening market in the future. Cancer occurs when certain cells in the human body grow abnormally and spread to other areas of the body. Population screening can facilitate early detection of cancer, making it more treatable and improving prognosis. For example, in January 2023, reports from the American Cancer Society Inc., a US-based voluntary health organization, indicated that there were 608,570 cancer deaths in 2022, alongside an estimated 1.9 million new cancer cases, compared to 606,520 cancer deaths in 2021. Therefore, the rising prevalence of cancer is fueling the growth of the population screening market.

The expanding proportion of aging individuals is anticipated to propel the growth of the population screening market. Aging individuals encompass those who are in the process of growing older or have reached advanced age milestones. Regular population screenings tailored to the specific health needs of aging individuals can significantly contribute to successful aging and better health outcomes. For instance, in June 2023, The United States Census Bureau, a governmental agency in the United States, reported a 0.2-year increase in the country's median age, reaching 38.9 years in 2022, indicating a continual aging trend within the population. Consequently, the growing proportion of aging individuals serves as a driving force behind the expansion of the population screening market.

Leading companies in the population screening market are developing advanced services like newborn mass screening to improve early detection and enhance infant health outcomes. Newborn mass screening is a public health initiative in which newborns are tested shortly after birth for various genetic, metabolic, hormonal, and functional disorders that may not be evident at birth but can result in serious health issues if untreated. For example, in May 2024, Shimadzu Techno-Research Inc., a contract analysis firm and subsidiary of Japan-based Shimadzu Corporation, launched a new contract service that conducts polymerase chain reaction (PCR) testing for expanded newborn mass screening. This service will screen for conditions like severe combined immunodeficiency (SCID), B-cell deficiency (BCD), and spinal muscular atrophy (SMA), which affect a small percentage of newborns but require immediate intervention upon diagnosis.

Major players in the population screening market are introducing new products for targeted disease screening to enhance their profitability. Specific disease screening within population screening refers to the focused identification of individuals at risk for certain diseases within a larger population. For instance, in October 2023, DELFI Diagnostics, a US-based company specializing in advanced machine learning and fragment omics, unveiled First Look Lung. This innovative blood test employs whole-genome machine learning to analyze cell-free DNA fragments as cancer markers. This convenient laboratory-developed test can be easily integrated into routine blood screenings. Its notable features include a 99.7% negative predictive value, effectively ruling out lung cancer, and high sensitivity for detecting early-stage disease. The test provides personalized, actionable reports to healthcare providers, offering a potential solution to improve the low lung cancer screening rates in the United States.

In January 2024, Natera, a US-based biotechnology firm, acquired Invitae for an undisclosed sum. This acquisition aims to broaden Natera's capabilities in non-invasive prenatal and carrier screening, enhancing its service offerings and supporting a larger number of patients and providers. Invitae is a US-based company that offers advanced genetic testing services, including those related to population screening.

Major companies operating in the population screening market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., SYNLAB International GmbH, Quidel Corporation, Bio-Rad Laboratories Inc., Unilabs, Qiagen N.V., Exact Sciences Corporation, ARUP Laboratories Inc., LGC Limited, OPKO Health Inc., Natera Inc., Cerba HealthCare S.A.S, Invitae Corp, Amedes Holding GmbH, Grail, Luminex Corporation, Novogene Co. Ltd., Trinity Biotech, Gene by Gene Ltd., Innova Medical Group Inc., Evoq Technologies LLC, LabPLUS

North America was the largest region in the population screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the population screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the population screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The population screening market consists of revenues earned by entities by providing services such as next-generation sequencing (NGS) and microarray-based genotyping, imaging tests, mammography screening, colonoscopy screening, cholesterol screening, and blood pressure screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The population screening market also includes sales of smartphone-based biosensors, kits, and chips, which are used in providing population screening services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Population Screening Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on population screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for population screening ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The population screening market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Population Screening Market Characteristics

3. Population Screening Market Trends And Strategies

4. Population Screening Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Population Screening Growth Analysis And Strategic Analysis Framework

6. Population Screening Market Segmentation

7. Population Screening Market Regional And Country Analysis

8. Asia-Pacific Population Screening Market

9. China Population Screening Market

10. India Population Screening Market

11. Japan Population Screening Market

12. Australia Population Screening Market

13. Indonesia Population Screening Market

14. South Korea Population Screening Market

15. Western Europe Population Screening Market

16. UK Population Screening Market

17. Germany Population Screening Market

18. France Population Screening Market

19. Italy Population Screening Market

20. Spain Population Screening Market

21. Eastern Europe Population Screening Market

22. Russia Population Screening Market

23. North America Population Screening Market

24. USA Population Screening Market

25. Canada Population Screening Market

26. South America Population Screening Market

27. Brazil Population Screening Market

28. Middle East Population Screening Market

29. Africa Population Screening Market

30. Population Screening Market Competitive Landscape And Company Profiles

31. Population Screening Market Other Major And Innovative Companies

32. Global Population Screening Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Population Screening Market

34. Recent Developments In The Population Screening Market

35. Population Screening Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기